MDC — Mediclinic International Share Price
Last trade - 00:00- £3.69bn
- £6.12bn
- £3.23bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 16.65 | ||
| PEG Ratio (f) | 1.47 | ||
| EPS Growth (f) | 12.81% | ||
| Dividend Yield (f) | 1.58% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.04 | ||
| Price to Tang. Book | 1.65 | ||
| Price to Free Cashflow | 7.86 | ||
| Price to Sales | 1.09 | ||
| EV to EBITDA | 11.95 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 3.95% | ||
| Return on Equity | 5.13% | ||
| Operating Margin | 7.98% | ||
Financial Summary
| Year End 31st Mar | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 2,876 | 2,932 | 3,083 | 2,995 | 3,233 | 3,460.72 | 3,566.36 | 3.3% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | +74.26 | -91.41 | +740.43 | +36.82 | +12.81 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Mediclinic International PLC is a United Kingdom-based diversified international private healthcare services company. The Company is focused on providing specialist-orientated, multi-disciplinary services. Its segments include Switzerland, Southern Africa and the Middle East. The Company comprises 74 hospitals, five subacute hospitals, three mental health facilities, 21 day case clinics and 23 outpatient clinics. It provides a range of clinical services across its divisions, including outpatient consultation services and pre-hospital emergency services, hospital-based emergency centers, day case surgery, acute care inpatient services, and highly specialized services. Its support services include laboratory, radiology, and nuclear medicine. The Swiss operations included 17 hospitals and five-day case clinics with around 1 900 inpatient beds; Southern Africa operations included 50 hospitals, five subacute hospitals, three mental health facilities and 14-day case clinics.
Directors
- Dame K. Beale NEC (57)
- Ronnie Van Der Merwe CEO (57)
- Jurgens Myburgh CFO
- David Hadley CEX
- Daniel Liedtke CEX
- Koert Pretorius CEX (57)
- Magnus Oetiker CHO
- Dirk Le Roux CIO
- Gert Hattingh OTH (54)
- Rene Toua OTH
- Tyson Welzel OTH
- Jannie Durand NED (54)
- James Alan Grieve NED (68)
- Danie Meintjes NED (64)
- Trevor Petersen NED
- Muhadditha Yahya Al Hashimi NID
- Natalia Barsegiyan NID
- Felicity Harvey NID
- Anja Oswald NID
- Tom Singer NID
- Steve Weiner NID
- Last Annual
- March 31st, 2022
- Last Interim
- September 30th, 2022
- Incorporated
- December 20th, 2012
- Public Since
- June 26th, 2013
- No. of Employees
- 34,964
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 737,243,810
- Address
- 6th Fl, 65 Gresham Street, LONDON, EC2V 7NQ
- Web
- https://www.mediclinic.com/
- Phone
- +44 2079549600
- Contact
- James Arnold
- Auditors
- PricewaterhouseCoopers LLP
Latest News for MDC
Upcoming Events for MDC
Mediclinic International PLC Annual Shareholders Meeting
Half Year 2024 Mediclinic International PLC Earnings Release
Similar to MDC
Burning Rock Biotech
London Stock Exchange
Chill Brands
London Stock Exchange
CVS
London Stock Exchange
Integrated Diagnostics Holdings
London Stock Exchange
IQ-AI
London Stock Exchange
FAQ
As of Today at 01:13 UTC, shares in Mediclinic International are trading at 501.00p. This share price information is delayed by 15 minutes.
Shares in Mediclinic International last closed at 501.00p and the price had moved by +34.24% over the past 365 days. In terms of relative price strength the Mediclinic International share price has outperformed the FTSE All Share Index by +37.42% over the past year.
The overall consensus recommendation for Mediclinic International is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Mediclinic International dividend yield is 0.6% based on the trailing twelve month period.
Last year, Mediclinic International paid a total dividend of £0.03, and it currently has a trailing dividend yield of 0.6%. We do not have any data on when Mediclinic International is to next pay dividends.
We do not have data on when Mediclinic International is to next pay dividends. The historic dividend yield on Mediclinic International shares is currently 0.6%.
To buy shares in Mediclinic International you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 501.00p, shares in Mediclinic International had a market capitalisation of £3.69bn.
Here are the trading details for Mediclinic International:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: MDC
Based on an overall assessment of its quality, value and momentum Mediclinic International is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Mediclinic International is 416.60p. That is 16.85% below the last closing price of 501.00p.
Analysts covering Mediclinic International currently have a consensus Earnings Per Share (EPS) forecast of £0.27 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mediclinic International. Over the past six months, its share price has outperformed the FTSE All Share Index by +1.68%.
As of the last closing price of 501.00p, shares in Mediclinic International were trading +0.84% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Mediclinic International PE ratio based on its reported earnings over the past 12 months is 16.65. The shares last closed at 501.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Mediclinic International's management team is headed by:
- Dame K. Beale - NEC
- Ronnie Van Der Merwe - CEO
- Jurgens Myburgh - CFO
- David Hadley - CEX
- Daniel Liedtke - CEX
- Koert Pretorius - CEX
- Magnus Oetiker - CHO
- Dirk Le Roux - CIO
- Gert Hattingh - OTH
- Rene Toua - OTH
- Tyson Welzel - OTH
- Jannie Durand - NED
- James Alan Grieve - NED
- Danie Meintjes - NED
- Trevor Petersen - NED
- Muhadditha Yahya Al Hashimi - NID
- Natalia Barsegiyan - NID
- Felicity Harvey - NID
- Anja Oswald - NID
- Tom Singer - NID
- Steve Weiner - NID